Clinical experience with eplerenone in the treatment of patients with acute coronary syndrome
DOI: 10.22138/2500-0918-2016-15-3-14-18
M.S. Ibragimov, A.N. Andreev, P.A. Kozlov, A.I. Milashchenko
Municipal budgetary central clinical city hospital No. 24, Department of Intensive Care, Yekaterinburg, Russian Federation;
Ural State Medical University, Yekaterinburg, Russian Federation
Abstract.
Eplerenone administration improves the prognosis for patients with myocardial infarction. Some trials have show a positive effect of aldosteron-receptor blockers on the frequency of re-hospitalization and decompensation of heart failure.The objective of this study was to assess the effect of eplerenone on NT-proBNP level as a combined therapy for ACS.89 patients with ACS and a previous history of coronary artery disease, hospitalized in intensive care unit, were enrolled in the study.We assessed the changes inNT-proBNP level in patients with ACS with and without ST-elevation. The study group was administered base-line therapy and eplerenone and control group was only base-line therapy. We found no significant difference in the level ofNT-proBNP between two groups.
Keywords:
acute coronary syndrome, eplerenone, brain natriuretic peptide
REFERENCES
1. Pitt B. et al. Eplerenone, а selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Меd 2003; 348 (14): 1309-21
2. Рitt В., Wbite Н., Nicolau J. еt al. Eplerenonerеduсеs mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dуsfunсtiоnапdhеаrt failure. J АmCollСаrdiol 2005;46 (3):425-31.
3. Zannad Р., Mcмиrray J.J., Кrиm Н. еt al. Eplerenone in patients with systolic heart fаilurеапd mild symptoms. N EnglМеd 2011; 364 (1): 11-21.
4. ESC Guidеlinеs for the diagnosis аnd treatment of acute апа chronic hеаrtfаilurе 2012. ЕurHeartJ 2012; 33: 1787-847
Authors
IbragimovMubariz S.
Ural State Medical University
PhD, Assistant Professor of Hospital TherapyDepartment
Russian Federation, 620219, Yekaterinburg, 3 Repina Str.
ibragimovmd@yandex.ru
Andreev Arkadij N.
Ural State Medical University
MD, Professor, Head of Hospital Therapy Department;
Russian Federation, 620219, Yekaterinburg, 3 Repina Str.
andart579@mail.ru
Kozlov Pavel A.
Ural State Medical University
Postgraduate of Hospital TherapyDepartment,
Russian Federation, 620219, Yekaterinburg, 3 Repina Str.
axe_p@mail.ru
Milashchenko Angeliya I.
Ural State Medical University
The second-year resident of Hospital TherapyDepartment
Russian Federation, 620219, Yekaterinburg, 3 Repina Str.
milashchenko-ai@yandex.ru
Received— 4.07.2016
Forcitation:IbragimovM.S., AndreevA.N., KozlovP.A., MilashchenkoA.I.Clinical experience with eplerenone in the treatment of patients with acute coronary syndrome. Vestn. Ural. Med. Akad. Nauki. – Journal of Ural Medical Academic Science. 2016, no. 3, pp. 14–18. DOI: 10.22138/2500-0918-2016-15-3-14-18 [In Russ.]
